Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   1/04/2026
75,71 USD (+5,23%)
(+5,23%)   1/04/2026
Grafiek Nektar Therapeutics Grafiek Nektar Therapeutics

Nektar Therapeutics in het nieuws

28 maart 2026 · Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting · Persbericht

26 maart 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR · Persbericht

24 maart 2026 · Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action · Persbericht

20 maart 2026 · Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting · Persbericht

19 maart 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR · Persbericht

16 maart 2026 · NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

12 maart 2026 · Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

12 maart 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR · Persbericht

12 maart 2026 · NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

7 maart 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Profiel Nektar Therapeutics

Biotechnologie
Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.nektar.com

Hoofdzetel: San Francisco, California vlag Verenigde Staten

Mijn selecties